California Resources Reports Third Quarter 2024 Financial and Operating Results
05. November 2024 16:31 ET
|
California Resources Corporation
California Resources Corporation Reports Third Quarter 2024 Financial and Operating Results
Carbon TerraVault Provides Third Quarter 2024 Update
05. November 2024 16:30 ET
|
Carbon TerraVault, LLC
Carbon TerraVault Provides Third Quarter 2024 Update
Kern County Board of Supervisors Advance CRC’s Carbon TerraVault I Project
21. Oktober 2024 17:00 ET
|
California Resources Corporation
Kern County Board of Supervisors unanimously approve the conditional use permit for CRC's Carbon TerraVault I carbon capture and storage project.
Colorado School of Mines and Carbon TerraVault Awarded $8.9 Million in DOE Funding for CarbonSAFE Project
08. Oktober 2024 09:00 ET
|
California Resources Corporation
Colorado School of Mines and Carbon TerraVault Awarded $8.9 Million in DOE Funding for CarbonSAFE Project
California Resources Corporation Schedules Third Quarter 2024 Earnings Conference Call
07. Oktober 2024 16:30 ET
|
California Resources Corporation
California Resources Corporation Schedules Third Quarter 2024 Earnings Conference Call for Wednesday, November 6, 2024 at 1:00 PM ET
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08. August 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
01. August 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
08. April 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Child Resistant Closures Market Size to Reach $3.44 Bn by 2028 | The Insight Partners
08. November 2023 08:54 ET
|
The Insight Partners
Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- According to our new research study, titled "Child Resistant Closures Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Material,...
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
04. Mai 2023 16:05 ET
|
Immuneering Corporation
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First...